News

A ‘Glimmer Of Hope’ In The Fight Against The World’s Top Infectious Killer


27 Sep 2017
by Working Group

In a sign of increasing political will in the battle against the world’s top infectious killer, the heads of the World Health Organization and USAID voiced their support for the global fight against tuberculosis last week in a reception during the United Nations General Assembly.

Advocates had been seeing a snowballing of political support to thwart tuberculosis, first with the announcement of a U.N. high-level meeting focused solely on TB next year, followed by the recent inclusion of the fight against TB in the G-20 declaration and excitement over a WHO ministerial conference on tuberculosis to be headlined by Russian President Vladimir Putin in November.  

WHO Director Tedros Adhanom Ghebreyesus spoke movingly of his brother’s fight against tuberculosis at the reception hosted Sept. 19 by the Stop TB Partnership and WHO, both part of the U.N. He stressed that TB continues to be a major problem today and that antimicrobial resistance is making it even more deadly. 

And the need for new drugs to combat tuberculosis, whose drug-resistant strains account for a third of antimicrobial-resistant (AMR) deaths, is growing. “Drug-resistant TB is the most common and lethal airborne AMR disease worldwide today, responsible for 250,000 deaths each year,” stated the WHO’s “Antibacterial Agents in Clinical Development” report, released last week.

Continue reading at HuffintonPost.com

More News
16 Nov 2017
Ending Tuberculosis Starts in Moscow (Op-ed) A meeting of the world’s health ministers in Moscow this week could prove to be a pivotal moment on the road to ending tuberculosis Nov 16, 2017 By José Luis Castro and Michel Kazatchkine A meeting of the world’s health ministers in Moscow this week...
9 Aug 2017
The United States Food and Drug Administration held a public workshop regarding scientific and clinical trial design considerations for development of new tuberculosis drug regimens. This public workshop was intended to provide information for and gain perspective pertaining to development efforts...
4 May 2017
Spero Therapeutics Receives Grant from National Institutes of Health to Explore Novel Treatment Combinations for Tuberculosis CAMBRIDGE, Mass., May 4, 2017—Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, today...